An Israeli company that has developed artificial intelligence that quickly diagnoses cancerous tumors has signed a $5 million agreement in India and Australia.
CuratioDL‘s AI is capable of diagnosing cancerous tumors in 10 common types of cancer, including lung, kidney, ovarian, breast, and more.
It helps pathologists who are not experts obtain expert-level decision support for cancer diagnoses and treatment recommendations.
The AI can also match a patient and their cancer subtype to the right drug for them. This, in addition to the quick diagnosis, contributes significantly to the patient’s chances of healing and recovery.
The agreement was signed with TechIndia Infoway, which provides services to hospitals in India and Australia.
CuratioDL’s first product will detect diagnostic priority between different biopsies and will be marketed in 2023 to pathology laboratories and hospitals.
During its development, the company took biopsy samples from around 7,000 patients, and had a 95 per cent success in the ability to diagnose a cancerous tumor.
Sign up for our free weekly newsletterSubscribe
“The agreement is very significant for the company since it opens up the potential for us to expand widely in Asia in general and India in particular,” said Rafi Heumann, CEO of CuratioDL.
“In India, more than 3.5 million new cases of cancer are discovered every year, with more than half of them being diagnosed in late stages of the disease.
“We believe that the company’s products will significantly improve the world of pathology while creating significant value for medicine, for the patients themselves while improving the time to diagnose, increase quality in order to provide personalized treatment that by end of the day- saves lives.
“A successful launch will enable entry into very attractive markets for us, as well as saving tens of millions of dollars a year for the medical system there.”
CuratioDL was founded in 2021 and is based in Herzliya, central Israel.